Skip to content

Study · Ex vivo tissue · 1985

6 results

Effect of thymulin on intracellular cyclic nucleotides and prostaglandins E2 in peanut agglutinin-fractionated thymocytes.

Rinaldi-Garaci C, Jezzi T, Baldassarre AM, Dardenne M, Bach JF, Garaci E

European journal of immunology1 Jun 1985Cited by 9 (Europe PMC)

PMID3859417 (opens in a new tab)DOI10.1002/eji.1830150604 (opens in a new tab)PepBankPUB-03859417
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    Thymulin increased the cAMP/cGMP ratio in isolated PNA+ thymocytes in a concentration-dependent manner.

    In plain wordsIn lab tests, thymulin increased the cAMP/cGMP ratio in immature thymocytes, depending on concentration.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseIntracellular cAMP/cGMP ratio
    Study

    n: not reported in source

    PNA+ immature thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data presented in this report show that thymulin is able to increase the cAMP/cGMP ratio in PNA+ and in unfractionated thymocytes, depending on its concentration, but not in PNA- thymic cells.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.
  2. 02LabEx vivo tissueMechanism

    Thymulin increased the cAMP/cGMP ratio in isolated unfractionated thymocytes in a concentration-dependent manner.

    In plain wordsIn lab tests, thymulin increased the cAMP/cGMP ratio in unfractionated thymocytes, depending on concentration.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseIntracellular cAMP/cGMP ratio
    Study

    n: not reported in source

    Unfractionated thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data presented in this report show that thymulin is able to increase the cAMP/cGMP ratio in PNA+ and in unfractionated thymocytes, depending on its concentration, but not in PNA- thymic cells.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.
  3. 03LabEx vivo tissueMechanism

    Thymulin did not increase the cAMP/cGMP ratio in isolated PNA- thymocytes.

    In plain wordsIn lab tests, thymulin did not increase the cAMP/cGMP ratio in mature thymocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeIntracellular cAMP/cGMP ratio
    Study

    n: not reported in source

    PNA- mature thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data presented in this report show that thymulin is able to increase the cAMP/cGMP ratio in PNA+ and in unfractionated thymocytes, depending on its concentration, but not in PNA- thymic cells.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.
  4. 04LabEx vivo tissueMechanism

    Thymulin increased PGE2 release from isolated PNA- thymocytes.

    In plain wordsIn lab tests, thymulin increased PGE2 release from mature thymocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreasePGE2 release
    Study

    n: not reported in source

    PNA- mature thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, it is able to increase the release of PGE2 by PNA- thymocytes but not by PNA+ and unfractionated thymic lymphocytes.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.
  5. 05LabEx vivo tissueMechanism

    Thymulin did not increase PGE2 release from isolated PNA+ thymocytes.

    In plain wordsIn lab tests, thymulin did not increase PGE2 release from immature thymocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changePGE2 release
    Study

    n: not reported in source

    PNA+ immature thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, it is able to increase the release of PGE2 by PNA- thymocytes but not by PNA+ and unfractionated thymic lymphocytes.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.
  6. 06LabEx vivo tissueMechanism

    Thymulin did not increase PGE2 release from isolated unfractionated thymocytes.

    In plain wordsIn lab tests, thymulin did not increase PGE2 release from unfractionated thymocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changePGE2 release
    Study

    n: not reported in source

    Unfractionated thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, it is able to increase the release of PGE2 by PNA- thymocytes but not by PNA+ and unfractionated thymic lymphocytes.
    2 context sentences
    Summary · context
    We have approached this area of investigation by studying the effects of thymulin (a serum thymus-derived factor, coupled with Zinc) on intracellular cAMP and cyclic GMP (cGMP) levels (expressed as cAMP/cGMP ratio) and on the release of PGE2 in different thymocyte subpopulations.
    Summary · context
    Thymocytes were fractionated by the peanut agglutinin (PNA) technique into cortical immature PNA+ and medullary mature PNA- thymocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.